highperformr logo

Cel-Sci's Overview

Total employees19
HeadquartersVienna
Founded

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to enhancing the treatment of cancer and other diseases by harnessing the power of the human immune system. The company's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is a novel immunotherapy being developed as a potential first-line neoadjuvant treatment for patients with advanced primary head and neck cancer. CEL-SCI's approach aims to stimulate the body's natural ability to fight disease, with a focus on improving patient outcomes and quality of life. The company is also exploring the utility of its LEAPS™ (Ligand Epitope Antigen Presentation System) technology for developing vaccines for infectious diseases and autoimmune disorders.

Where is Cel-Sci's Headquarters?

HQ Function

The headquarters serves as the central hub for corporate administration, strategic leadership, investor relations, financial operations, and regulatory affairs management.

Notable Features:

Situated in a modern office complex within a well-established business park, offering a professional environment and good transportation links. The focus is on functional office space suited for corporate operations.

Work Culture:

The work culture at CEL-SCI's headquarters is likely characterized by a strong sense of purpose, driven by the pursuit of scientific innovation and the development of life-changing therapies. It likely fosters collaboration, dedication, and a focus on achieving clinical and regulatory milestones.

HQ Significance:

Its location in the greater Washington D.C. area provides strategic advantages, including proximity to regulatory agencies like the U.S. Food and Drug Administration (FDA), access to a skilled talent pool, and connections with the broader biotech and investment community.

Values Reflected in HQ: The choice of a professional and accessible headquarters reflects CEL-SCI's commitment to operational excellence, strategic engagement with stakeholders, and its mission-driven focus on advancing medical science.

Location:

While CEL-SCI's core administrative, research, and manufacturing operations are based in the United States (Virginia and Maryland), its clinical development program for Multikine has a significant global reach. The pivotal Phase 3 study for Multikine in head and neck cancer involved clinical trial sites in numerous countries across North America, Europe, and Asia. This international clinical trial footprint underscores CEL-SCI's strategy to develop therapies for global patient populations and to seek regulatory approvals in multiple major markets worldwide. The company's global presence is primarily driven by its clinical research activities and collaborations rather than a network of international offices.

Street Address:

8229 Boone Boulevard, Suite 802

City:

Vienna

State/Province:

Virginia

Country:

USA

Cel-Sci's Global Presence

Near Baltimore, Maryland, USA

Address: Specific address for the manufacturing/R&D facility near Baltimore (e.g., 1450 South Rolling Road, Baltimore, MD 21227, though this is a research park address they lease space in; exact dedicated facility address might be less public). The company leases approximately 41,000 square feet.

Located in the Maryland biotech corridor, this site benefits from access to specialized scientific talent, research institutions, and infrastructure supportive of biopharmaceutical manufacturing and R&D.

Buying Intent Signals for Cel-Sci

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cel-Sci

As of April 2025, Cel-Sci' leadership includes:

Geert R. Kersten - Chief Executive Officer, Director
Eyal Talor, Ph.D. - Chief Scientific Officer, Director
Patricia B. Bendeck - Senior Vice President, Operations and Director
John L. Cipriano - Senior Vice President, Regulatory Affairs
Jonathan F. Hale - Chief Financial Officer

Investors of Cel-Sci

Cel-Sci has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock Inc.
Geode Capital Management, LLC
State Street Corporation
Millennium Management LLC
Ergomed PLC (as a clinical research organization that also made an investment)

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

In the past year, CEL-SCI Corporation strengthened its executive team with a key appointment in financial leadership, appointing a new Chief Financial Officer.

Departures

Denise DeSimone, Denise DeSimone transitioned from her role as Chief Financial Officer. She remains with the company in a consulting capacity.

New Appointments:

Jonathan F. Hale, Jonathan F. Hale was appointed as the new Chief Financial Officer, bringing extensive experience in finance and biotechnology.

Technology (Tech Stack) used by Cel-Sci

Discover the tools Cel-Sci uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cel-Sci Email Formats and Examples

CEL-SCI Corporation's email addresses likely follow common corporate patterns, typically combining elements of an employee's name with the company domain 'cel-sci.com'. Standard formats facilitate professional communication.

Common formats include [firstinitial][lastname]@cel-sci.com (e.g., jdoe@cel-sci.com) or [first].[lastname]@cel-sci.com (e.g., jane.doe@cel-sci.com).

Format

info@cel-sci.com (General contact, other specific emails may follow patterns like jsmith@cel-sci.com)

Example

70%

Success rate

News and media

GlobeNewswireMay 15, 2024

CEL-SCI Reports Second Quarter Fiscal 2024 Financial Results and Clinical Development Update

CEL-SCI Corporation announced its financial results for the quarter ended March 31, 2024, and provided updates on its Multikine clinical development program, including interactions with regulatory authorities and manufacturing activities....more

SEC FilingApril 29, 2024

CEL-SCI Corporation Files Definitive Proxy Statement for 2024 Annual Meeting of Stockholders

CEL-SCI filed its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission for its 2024 Annual Meeting of Stockholders, detailing proposals for stockholder voting....more

GlobeNewswireDecember 18, 2023

CEL-SCI Corporation Appoints Jonathan F. Hale as Chief Financial Officer

CEL-SCI announced the appointment of Jonathan F. Hale as its new Chief Financial Officer, effective December 18, 2023. Mr. Hale brings over 20 years of financial and operational experience to the role....more

GlobeNewswireFebruary 14, 2024

CEL-SCI Reports First Quarter Fiscal 2024 Financial Results

CEL-SCI Corporation reported its financial results for the first fiscal quarter ended December 31, 2023, and provided a corporate update on its programs....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cel-Sci, are just a search away.